NVO vs VKTX

Novo Nordisk (NVO) continues its impressive trajectory, cementing market leadership in diabetes and obesity with its dominant GLP-1 franchise. The company boasts robust financials, a formidable competitive moat from proprietary assets and R&D, and a clear strategic vision for expanding therapeutic applications. However, the core mandate of identifying 10x growth potential within 3-5 years from its...

Viking Therapeutics maintains its strong 10x growth potential, with no material changes since the last analysis warranting a significant score adjustment. The company's lead asset, VK2735, a dual GLP-1/GIP agonist, continues to be a compelling candidate in the lucrative metabolic disorder market. Positive Phase 2 data for both injectable and oral formulations positions it as a potential best-in-cl...